A- A A+

COVID-19: guidance for commissioners and providers of services for people who use drugs or alcohol 

Guidance for commissioners and service providers for those dependent on drugs or alcohol.

Public Health England and Department of Health and Social Care 

Published: 15 April 2020


USA. ASAM: COVID-19 - National and State Health Guidance

This webpage contains news, guidance and resources from around the country regarding addiction treatment in the wake of COVID-19. (ASAM – American Society of Addiction Medicine, 2021)


USA:. HS Expands Access to Treatment for Opioid Use Disorder 

The U.S. Department of Health and Human Services is publishing Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder*, to expand access to medication-assisted treatment (MAT) by exempting physicians from certain certification requirements needed to prescribe buprenorphine for opioid use disorder (OUD) treatment. (HHS, USA, Januar 2021)


USA. Ongoing Management of the Continuum of Addiction Care During COVID-19

A guide for addiction treatment clinicians and programs working to treat patients with substance use disorders safely and effectively during the COVID-19 pandemic. (ASAM – American Society of Addiction Medicine, 2020)


Preventing problematic internet use during the COVID-19 pandemic: Consensus guidance. 

Király O, Potenza MN, Stein DJ, et al. 

Compr Psychiatry. 2020;100:152180. doi:10.1016/j.comppsych.2020.152180



Kanada. Supporting people who use substances in shelter settings during the COVID‐19 pandemic - NATIONAL RAPID GUIDANCE 

Hyshka, K., Dong, K., Meador, K., Speed, K., Abele, B., LeBlanc, S., McFarlane, A., McNeil, R., Salokangas, E., Schoen, E., & Wild, T.C. 

Edmonton, Alberta: Canadian Research Initiative in Substance Misuse; May 17, 2020. 82 p. Version 1. 


USA. ASAM releases major updates to COVID-19 guidance documents and resources regarding addiction treatment in the wake of COVID-19

As the leader in developing clinical guidelines and standards in addiction medicine, the American Society of Addiction Medicine takes our responsibility very seriously.  We convened the ASAM Caring for Patients During the COVID-19 (CPDC) Task Force to rapidly develop guidance tailored to addiction medicine treatment within the context of the COVID-19 pandemic. (American Society of Addiction Medicine, 18.09.2020)


WHO Europes Guidance on COVID-19 and alcohol

The following factsheet from WHO Europe provides important information that you should know about alcohol consumption and COVID-19. It addresses, among other things, the misinformation that is being spread through social media and other communication channels about alcohol and COVID-19.


Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic

Mauri, DavidePetricevic, Branka et al.

The Lancet Oncology, Volume 0, Issue 0


Interim Guidance for COVID-19 and Persons with HIV

This interim guidance reviews special considerations for persons with HIV and their health care providers in the United States regarding COVID-19. Information and data on COVID-19 are rapidly evolving. This guidance includes general information to consider. People with HIV who have COVID-19 have an excellent prognosis, and they should be clinically managed the same as persons in the general population with COVID-19, including when making medical care triage determinations. (US Departement of Health and Human Services, Last Updated: April 21, 2020; Last Reviewed: April 21, 2020)



Herausgeber: Stadt Zürich, Soziale Einrichtungen und Betriebe


Schweiz. Suchthilfe und COVID-19 

Empfehlungen zum Umgang mit der COVID-19-Pandemie von Fachpersonen aus dem Suchtbereich 

Das vorliegende Dokument fasst Beobachtungen von Fachpersonen aus dem Suchtbereich zusammen und enthält Handlungsempfehlungen für Institutionen und Fachperso-nen aus dem Suchtbereich zum Umgang mit COVID-19. Gefordert wird ein verstärkter Schutz für die vulnerable Gruppe der Betroffenen und für Fachpersonen und damit auch eine grössere Flexibilität in der Anwendung der geltenden Bestimmungen. Die Empfehlungen dienen der Unterstützung der zahlreichen öffentlichen und privaten gemeinnützigen Akteure, die sich bereits jetzt stark und pragmatisch engagieren. Nur mit einem starken und funktionierenden, gut und niederschwellig verfügbaren Behandlungs- und Betreuungssystem können Betroffene und die Bevölkerung geschützt und Massnahmen zur Eindämmung der COVID-19-Pandemie umgesetzt werden. (GREA, ticino, Fachverband Sucht, Föderation der Suchtfachleute, SSAM und Sucht Schweiz, Lausanne, Bern, Zürich, Lugano, 02.04.2020)


Schottland. Guidance on contingency planning for people who use drugs and COVID-19

Guidance has been produced on contingency planning for people who use drugs and COVID-19 and has been shared with all Alcohol and Drug Partnerships and all drug services in Scotland. (SDF – Scottish Drugs Forum, April 2020)


USA. FAQs: Provision of methadone and buprenorphine

SAMHSA, USA, Updated 21.04.2020)


UNODC. Suggestions about treatment, care and rehabilitation of people with drug use disorder in the context of the COVID-19 pandemic 

A contribution to the health security of countries and communities.(UNODC, April 2020)


Preventing COVID-19 outbreak in prisons: a challenging but essential task for authorities

Today, WHO/Europe has published interim guidance on how to deal with the coronavirus disease (COVID-19) in prisons and other places of detention, entitled “Preparedness, prevention and control of COVID-19 in prisons and other places of detention”. (WHO Regional Office for Europe, 23.03.2020)


Kanada - British Columbia. COVID-19: Information for Opioidagonist Treatment Presribers and Pharmacists
March 17, 2020 

BCCSU – British Columbia Centre on Substance Use, 17.032020



BCCSU – British Columbia Centre on Substance Use, März 2020, Version 1.2 


Kanada. COVID-19 pandemic pushes B.C. to move forward on safe take-home drug supply strategy 

(…)  While opioids are the main driver of B.C.’s overdose crisis, the new guidelines extend to other substances, such as stimulants, benzodiazepines, tobacco and alcohol.

Prescribed stimulants include dextroamphetamine (trade name Dexedrine), while benzodiazepines include clonazepam. Those with tobacco-use disorder can be provided with nicotine replacement therapies such as the patch or gum, while medications used to manage alcohol withdrawal include gabapentin and clonidine.

Donald MacPherson, executive director of the Canadian Drug Policy Coalition, said Thursday he was simultaneously delighted and astounded by the development. (Globe and Mail, Kanada, 26.03.2020)


Schweiz. Diamorphinsubstitution: Stellungnahme des BAG zu HeGeBe unter dem Eindruck des Corona-Virus

Das BAG nimmt Stellung (pdf, 2S.) zu den eingegangenen Fragen bezüglich der aktuellen Herausforderungen der HeGeBe Institutionen im Zusammenhang mit COVID-19. (Bundesamt für Gesundheit, Bern, 13.03.2020)


Norwegen. Information from the Norwegian Centre for Addiction Research (SERAF), University of Oslo, Norway, about special measures for vulnerable groups with substance use disorders (SUD) during the Coronavirus epidemic

UIO – Institut of Clinical Medicie, Faculty of Medicine, Prof. Dr. med. Thomas Clausen, Norwegen, 15.03.2020)


Australien. Guidance for AOD Services about COVID-19

New South Wales Government, Health, wird laufend aktualisiert


New York. New York State Office of Addiction Services and Supports – Opioid Treatment Programmes (OTP)  and Covid-19.

(OASAS - New York State Office of Addiction Services and Supports, 10.03.2020.)


Wien. PatientInnen-Information zur Heimquarantäne und Medikamentenversorgung

(Suchthilfe Wien, Österreich, 24.03.2020)

240320 Wien Info_Aufsuchende Notversorgung_SHW_PatientIn_ZuweiserInnen

Wien. Prozess der Sicherstellung der Substitutionsmedikation bzw. Psychopharmaka bei PatientInnen in Heimquarantäne

(Suchthilfe Wien, Österreich, 24.03.2020 )

240320 Wien Grafik Ablauf COVID-19 Substitution-Psychopharmaka Heimquarantäne.pdf

Österreich/Wien. COVID-19 Ablauf Versorgung von PatientInnen mit Substitutions- bzw. Psychopharmakologischer Medikation zur Entlastung des Gesundheitssystems

(Suchthilfe Wien, Österreich, 24.03.2020 )

240320_Wien. Ablauf_COVID19-Substitution-Psychopharmaka

Opioidagonistentherapie (OAT) und COVID-19 Pandemie: Empfehlungen der Schweizerischen Gesellschaft für Suchtmedizin (SSAM) 

Mit der zunehmenden Ausbreitung des COVID-19 stehen wir in unseren Praxen und Institutionen bezüglich der Behandlung von Personen mit Opioidabhängigkeit vor gros- sen Herausforderungen. 

Die in diesem Dokument zusammengefassten Empfehlungen stellen den aktuellen Stand der Erkenntnisse dar und werden laufend auf unserer Homepage aktualisiert. Die spezifischen kantonalen Richtlinien sind unabhängig davon zu berücksichtigen. Die entsprechenden Links finden Sie unter Praxis Suchtmedizin Schweiz oder In- fodrog. (SSAM – Schweizerische Gesellschaft für Suchtmedizin, 24.03.2020)


USA. Use of Telemedicine While Providing Medication Assisted Treatment (MAT) 

(US Department of Justice, Drug Enforcement Administration, Diversion Control Division, 15.05.2018)


China. Leitlinie zum Umgang mit der Coronavirus-Epidemie (dt. Übersetzung)

Version 7, China, 16.03.2020


AATOD Guidance to OTPs in Response to the Coronavirus (COVID-19) 

Maintaining Adequate Supplies of Medications and Other Vital Materials
OTPs should determine their medication management needs in order to ensure they have the proper inventory needed to treat patients effectively as more take-home medication will be required, especially if the program falls within a quarantine zone. Inventory also includes medical supplies and equipment that the programs will need to function and effectively treat patients. Please keep in mind that this is a rapidly changing event and programs need to be as prepared as possible to deal with such ongoing challenges. (AATOD – American Association fort he Treatment of Opioid Dependence, 20.03.2020)